The folic acid analog trimethoprim has been in clinical use for more than 10 years. The use of it in Sweden has doubled in the last 6 to 7 years, and from the distribution statistics it can be calculated that during 1 year 4 to 5% of the population in Sweden are given this drug. The The folic acid analog trimethoprim has been used as an antimicrobial agent for more than a decade. A few years after the introduction of trimethoprim for clinical use, R plasmid-mediated resistance to this drug was reported (13). This plasmid-borne resistance also demonstrated a new principle regarding bacterial insensitivity, in that a drug-resistant variation of the target enzyme, dihydrofolate reductase, was found to be expressed from the plasmid (1, 22). Several types of plasmid-borne, drug-resistant dihydrofolate reductases have been subsequently discerned, and at least one of them was shown to be located on a transposon, Tn7 (3, 4). In later years, trimethoprim has been used extensively for clinical purposes, and resistance to it seems to have increased in frequency (7, 9, 25) .
The folic acid analog trimethoprim has been used as an antimicrobial agent for more than a decade. A few years after the introduction of trimethoprim for clinical use, R plasmid-mediated resistance to this drug was reported (13) . This plasmid-borne resistance also demonstrated a new principle regarding bacterial insensitivity, in that a drug-resistant variation of the target enzyme, dihydrofolate reductase, was found to be expressed from the plasmid (1, 22) . Several types of plasmid-borne, drug-resistant dihydrofolate reductases have been subsequently discerned, and at least one of them was shown to be located on a transposon, Tn7 (3, 4) . In later years, trimethoprim has been used extensively for clinical purposes, and resistance to it seems to have increased in frequency (7, 9, 25) .
The use of trimethoprim in Sweden can be defined quantitatively by data from the computerized Swedish Drug Information System (Department of Drugs, National Board of Health and Welfare). From these data it could thus be seen that more than 0.15% of the population receive trimethoprim each day or that during 1 year 4 to 5% of the population are given this drug. It was interesting to investigate the types of bacterial resistance mechanisms that could be found in response to such a selection pressure in a relatively isolated population in northern Sweden (the county of Jamtland), in which one centrally located bacteriological laboratory serves the area. During an 8-month period, trimethoprim-resistant strains were collected from consecutive specimens of bacteria from the urinary tracts of patients. Among highly resistant bacteria, transposon Tn7 was found to be common, either located chromosomally or borne on a conjugative Incl plasmid, 50 kilobases (kb) of size, which seemed to be endemic to the area. Two cases of marked overproduction of chromosomal dihydrofolate reductase which caused high resistance to trimethoprim were also found.
* Corresponding author.
MATERIALS AND METHODS
Bacterial strains and plasmids. Laboratory strains of bacteria and plasmids are listed in Table 1 . Clinically isolated enterobacterial strains are listed in Table 2 , and their collection is described in the text. Testing for antibiotic resistance was performed by the agar diffusion method with antibiotics-containing paper disks from AB Biodisk, Solna, Sweden.
The serotyping of Escherichia strains was kindly performed by I. and F. Orskov, International Escherichia and Klebsiella Centre, Copenhagen.
Media. The rich medium LB or the mineral salts medium M9, supplemented with Casamino Acids (0.05% [wt/vol]), was used throughout (19) .
Transfer of R plasmids. The transfer of R plasmids was performed as described earlier (21) and also on agar plates, and recombinants were selected on M9 agar plates containing the appropriate antibiotics.
Plasmid DNA preparation. The procedure described earlier for the isolation of small plasmids was used (17) . For larger R plasmids, the method described by Hansen and Olsen was used (12 (17) .
Enzyme preparation and assay. Dihydrofolate reductase was extracted and partially purified as described by Tennhammar-Ekman and Skold (24) . The final step in this procedure was ion-exchange chromatography on DEAESephacel (Pharmacia Fine Chemicals, Uppsala, Sweden). Material from a 700-ml bacterial culture was chromatographed on a column (0.9 by 15 cm) and eluted at a rate of 12 mlI/h by a linear gradient of 0.05 to 0.50 M KCl in 0.05 M Tris-chloride buffer (pH 7.2) containing 1 mM dithiothreitol. Enzyme activity was determined as described by Warner and Lewis (26) , and tests for inhibition by trimethoprim were performed by adding the drug to the indicated final concentration 2 min before the addition of dihydrofolate, which started the reaction. Enzyme assays on crude extracts were performed several times and agreed to within 10%o.
Colony hybridization. Colony hybridization was performed as described by Grunstein and Hogness (11) coli of at least three different serotypes (Table 2) . Furthermore, the original strains were isolated from several geographically separated locations. Table 2 lists all enterobacteria occurring among the collected strains, and it can be seen that although drug-resistant enzymes of type I (found in Tn7) dominated as the mechanism of resistance to trimethoprim, there were also two cases of increased production of indigenous chromosomal dihydrofolate reductase represented by one E. coli and one Proteus vulgaris strain. Crude extracts from cells of these strains showed dihydrofolate reductase activities which were ca. 80-fold higher than in similar extracts from E. coli K-12 (Table 3) . Partially purified enzyme from these extracts showed only one increased peak of activity at the chromatographic position of chromosomal dihydrofolate reductase, which is distinct from the corre- T118 (see Table 2 ) .38.9 T142 (see Table 2 ) .41.0 C600 (R483 dihydrofolate reductase as a mechanism of trimethoprim resistance in a clinical isolate has been described previously (8) .
Characterization of the transferable plasmid R2258. Purified DNA of R2258 was introduced by transformation into the E. coli strain C600 containing the IncI plasmid R144 (Table 1) . Transformants were selected on plates containing trimethoprim and tetracycline, picked and grown on drugfree plates, and finally replica plated on medium containing trimethoprim or tetracycline.
Of 100 colonies tested from each type of plate, 92 of those that grew in the presence of tetracycline were also trimethoprim resistant, whereas only 12 of those from the trimethoprim replica plate were also resistant to tetracycline, These data are interpreted to reflect incompatibility between R144 and R2258, i.e., that the latter belongs to compatibility group IncI. The large number of trimethoprim-resistant colonies observed on the tetracycline plate could be explained by the transposition of the Tn7-like transposon from R2258 to the host chromosome. This interpretation was supported by the observations that none of these doubly resistant strains was able to transfer trimethoprim resistance by conjugation with a plasmid-free recipient strain and that the expression of dihydrofolate reductase was lower (Table 3) .
That the Tn7-like transposon readily transposes from R2258 was shown in an experiment in which R2258 was transformed into E. coli C600 harboring plasmid pLGL1 (Table 1) which contains a fragment of host chromosomal DNA, which in turn contains the specific chromosomal receptor site for Tn7 (15) . In four of six electrophoretically analyzed transformants, a plasmid of 20 kb which was distinct from both R2258 and pLGLl was found. During the transformation of strain C600, this plasmid was found to specify trimethoprim as well as streptomycin and spectinomycin resistance. Restriction enzyme digestion analysis furthermore showed this plasmid to be identical with pLGL1::Tn7 (15) (Fig. 1 ).
Other plasmids, such as R483 and R721 (Table 1) , have previously been shown to contain Tn7. Lichtenstein and Brenner (15, 16) demonstrated that Tn7 has a unique insertion site on the chromosome of E. coli K-12. A 1-kb EcoRI fragment containing this site was isolated by the same authors and inserted into plasmid pACYC184 to give hybrid plasmid pLGL1 (15) .
This small chromosomal EcoRI fragment was labeled with 32p as described above and used as a probe in DNA-DNA hybridization of electrophoretically separated EcoRI fragments from plasmids R2258, R721, and R483. No hybridization was observed, which indicated that there are no extensive homologies between the chromosomal and the plasmid insertion sites for Tn7, as could be expected when the unique insertion site of Tn7 observed in the bacterial chromosome (15, 16) also occurred in plasmids.
Expression ofdihydrofolate reductase from plasnid R2258. The dihydrofolate reductase activity expressed from R2258 is twice that expressed from R483 (Table 3) . When enzyme expression from the chromosomally located Tn7-like transposon derived from R2258 was compared with the analogous expression from Tn7 transposed from R483, however, the activities were about the same (Table 3 ). This is interpreted as demonstrating that there exists a constitutive expression of dihydrofolate reductase from Tn7 and that the mentioned difference between cells containing R2258 and those containing R483 was due to different plasmid copy numbers. DISCUSSION The large consumption of trimethoprim as an antibacterial drug could be expected to evoke a response of resistance among pathogenic bacteria. It was interesting to investigate this response regarding resistance mechanisms among human urinary tract pathogens in a geographical area in which representative bacterial specimens could be obtained. The county of Jamtland in Sweden has a population of 128,000, which is served by a centrally located bacteriological laboratory.
Almost a third of the 153 consecutively collected trimethoprim-resistant strains showed high-level resistance (MIC, >l03 ,g/ml) to the drug. Fifteen of the 21 enterobacteria belonging to this highly resistant group of strains hybridized to a probe that represented the trimethoprim resistance expressing part of transposon Tn7. Since the serotypes and also the resistance patterns of these strains, which were all E. coli, were quite variable, this observation indicates that the gene expressing the trimethoprim-resistant dihydrofolate reductase of type I and previously found to be mediated by transposon Tn7 is efficiently spread among enterobacterial strains in this area.
Six of the highly resistant enterobacterial strains that hybridized to the Tn7-derived probe could transfer their trimethoprim res~istance to a susceptible recipient. In all six cases, the transfer was mediated by the same 50-kb IncI plasmid. This was determined from the identity of fragment patterns during gel electrophoresis of purified plasmid DNA from the different strains after digestion with the restriction enzyme HpaI. The bacterial strains in which the plasmid was originally demonstrated were of at least three different serotypes and were furthermore isolated from several geographically separated areas. This could be interpreted as the, occurrence of a plasmid endemic to the area which efficiently transferred Tn7-mediated trimethoprim resistance. This transferable plasmid was shown to be able to transpose a piece of DNA corresponding to the size (14 kb) of Tn7 to plasmid pLGL1, which contains the Tn7-specific receptor from the E. coli chromosome (16) . The resulting plasmid was indistinguishable from pLGL1::Tn7 during gel electrophoresis after digestion with the restriction enzyme AvaI (Fig. 1,   lanes g and h) . Nine of the isolated strains of E. coli reacted with the Tn7-specific probe at colony hybridization but did not transfer trimethoprim resistance at conjugation. Since transposon Tn7 is known to transpose readily to the chromosome of E. coli, these strains most likely have trimethoprim resistance genes (identified by the probe) borne on a Tn7-like transposon on the chromosome.
It was proposed earlier that the overproduction of chromosomal dihydrofolate reductase ought to be an unlikely cause of resistance to trimethoprim among bacteria because of the presumed harmful metabolic effects of large intracellular amounts of this enzyme (14) . In contrast to this proposition, we found that in two enterobacterial strains, resistance to more than 103 ,ug of trimethoprim per ml was caused by a ca. 80-fold increase in the formation of chromosomal dihydrofolate reductase. These two cases, together with one studied earlier (8) , thus seem to establish the overproduction of chromosomal dihydrofolate reductase as a mechanism of antifolate resistance among pathogenic enterobacteria.
In summary, the dissemination of transposon Tn7, both plasmid borne and chromosomally located, seems to be the 
